Press Releases

The Board of Indivior PLC today announces the appointment of Barbara Ryan as an Independent Non-Executive Director

Slough, UK, and Richmond, VA, April 27, 2022 - The Board of Indivior PLC today announces the appointment of Barbara Ryan as an Independent Non-Executive Director of the Company with effect from June 1, 2022.

Graham Hetherington, Chair, commented:

‘We are pleased to have Barbara join Indivior’s Board as an Independent Non-Executive Director. With over 40 years of experience in US healthcare capital markets, she will be a tremendous asset as we look to broaden Indivior’s awareness in the US.  She will also bring important perspectives as we seek to grow Indivior through potential business development opportunities."

Barbara was a Wall Street sell-side research analyst covering the US Large Cap Pharmaceutical Industry for more than 30 years before founding Barbara Ryan Advisors, a capital markets and communications firm, in 2012. Barbara has deep experience in equity and debt financings, M&A, valuation, SEC reporting, financial analysis and corporate strategy across a broad range of life sciences companies. Barbara is also the Founder of Fabulous Pharma Females, a non-profit organization whose mission is to advance women in the biopharma industry.  Barbara is a Senior Advisor at EY and is currently a Non-Executive Director of INVO Bioscience (Nasdaq: INVO) and MINK Therapeutics (Nasdaq: INKT).

There is no further information to disclose in relation to Barbara Ryan's appointment in accordance with LR 9.6.13.

About Indivior

Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting



Jason Thompson
Vice President, Investor Relations
+1 804 402 7123